Nutralliance has signed an agreement with Eggnovo, an ingredient supplier based in Navarra, Spain, to represent and market its Ovoderm and Ovomet ingredients in the U.S., with a primary focus on the ingredients as a source of collagen.
 
Eggnovo specializes in functional branded ingredients derived from chicken eggshells for nutraceuticals, cosmetics, and the pharmaceutical industry.
 
“Eggshell-derived ingredients have powerful attributes to human health, and Eggnovo is one of the world’s premiere suppliers of well-researched eggshell compounds,” said Brian Salerno, CEO of Nutralliance. “Eggnovo’s ingredients, chiefly Ovederm for the beauty-from-within market and Ovomet for the joint health market, strategically bolster our selection of quality ingredients for the dietary supplement manufacturing industry in North America.”

Ovoderm has been researched for its role in promoting healthy skin through improving barrier function, and a reduction of visible signs of skin aging. Skin elasticity and firmness were improved, which helps to reverse age-induced elasticity, according to the company.
 
Citing Coherent Market Insights, Nutralliance reports that the beauty supplements market reached nearly $2.5 billion in 2018, and is expected to grow to approximately $3.7 billion in 2027.
 
“As consumers learn about how their skin can be damaged by the elements and lifestyle factors, they are also learning how to use supplements to counteract the damage and restore healthy barrier function and youthful texture. Ovoderm addresses both goals,” Salerno said.
 
Eggnovo’s patented Ovomet is a natural matrix of active substances such as elastin, collagen (types I, V, and X) chondroitin sulfate, hyaluronic acid, and glucosamine, in addition to 400 proteins. A study appearing in the Journal of Clinical Rheumatology demonstrated that supplementing with 300 mg of Ovomet daily reduced joint discomfort and dysfunction in osteoarthritis patients as early as the first five days compared to those taking a placebo.